Keyphrases
Metastatic Castration-resistant Prostate Cancer (mCRPC)
88%
Prostate Cancer
77%
Tumor
74%
Chemerin
60%
Tumor Microenvironment
53%
Nivolumab
44%
Natural Killer Cells
43%
Sipuleucel-T
42%
Clear Cell Renal Cell Carcinoma (ccRCC)
41%
Metastatic Renal Cell Carcinoma (mRCC)
40%
T Cells
38%
Androgen Deprivation Therapy
38%
Overall Survival
38%
Immune Response
32%
Integrin
31%
CheckMate
29%
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
27%
Advanced Prostate Cancer
26%
Adhesion
25%
In Cancer
23%
Docetaxel
23%
Cancer Immunotherapy
23%
Tumor Cells
22%
Chemokines
22%
CD137
21%
Ipilimumab
20%
MAdCAM-1
20%
Chemotherapy
19%
Urothelial Carcinoma
19%
Checkpoint Inhibitor Immunotherapy
19%
Anti-lymphoma
19%
First-in-human
19%
Essential Pathway
19%
Brain Metastases
19%
Epigenetics
19%
Anti-CD20 Antibody
19%
Transcriptomic Characterization
19%
Progression Markers
19%
Spatial Proteomics
19%
Multiparametric MRI (mpMRI)
19%
Clinically Significant Prostate Cancer
19%
Nivolumab Plus Ipilimumab
19%
Advanced Renal Cell Carcinoma
19%
Chemoattractant
19%
Monotherapy
19%
Prostate-specific Antigen
19%
Clinical Trials
19%
Clinical Outcomes
18%
Tumor Growth
18%
Prostate Cancer Patients
18%
Medicine and Dentistry
Prostate Cancer
100%
Castration Resistant Prostate Cancer
64%
Immunotherapy
54%
Neoplasm
42%
Clear Cell Renal Cell Carcinoma
42%
Proteomics
29%
Malignant Neoplasm
27%
Overall Survival
27%
Nivolumab
26%
Sipuleucel T
25%
Clinical Trial
23%
Androgen Deprivation Therapy
23%
Diseases
23%
Bladder Cancer
21%
Kidney Metastasis
20%
Brain Metastasis
19%
Chemoradiotherapy
19%
Magnetic Resonance Imaging
19%
Metastatic Carcinoma
18%
Transitional Cell Carcinoma
18%
Prostate Specific Antigen
17%
Immune Response
17%
T Cell
16%
Ipilimumab
15%
Adverse Event
15%
Immune Checkpoint Blockade
14%
Progression Free Survival
14%
Radiation Therapy
14%
Homologous Recombination
13%
Systemic Therapy
12%
Antineoplastic Activity
12%
Fluorine-18
12%
Immune Checkpoint Inhibitor
12%
Mass Cytometry
11%
Rucaparib
11%
CD137
11%
Radiopharmaceutical
11%
Natural Killer Cell
10%
Melanoma
10%
Transcriptomics
10%
Cabozantinib
9%
Retrospective Cohort Study
9%
Positron Emission Tomography
9%
PARP1
9%
Sodium Fluoride
9%
Muscle Invasive Bladder Cancer
9%
Cancer Recurrence
9%
Metal Organic Framework
9%
Antibody Therapy
9%
Squamous Cell Carcinoma
9%
Immunology and Microbiology
Chemerin
57%
Prostate
54%
Immunity
52%
Natural Killer Cell
48%
T Cell
42%
Immunotherapy
41%
Leukocyte
35%
Sipuleucel-T
32%
Immune Response
29%
Immunocompetent Cell
23%
Tumor Cell
23%
Integrin
21%
Transcriptomics
20%
Chemokine
20%
Cell Adhesion Molecule 1
19%
Magnetic Resonance Imaging
19%
Proteomics
19%
Cancer Immunotherapy
18%
Chemoattractant
18%
Nivolumab
18%
Cytotoxic T-Cell
17%
Effector Cell
17%
Immune Checkpoint Blockade
13%
Lymphocyte
12%
Cell Function
11%
Thymus
10%
Plasmacytoid Dendritic Cell
10%
Melanoma Antigen
9%
Tumor-Associated Macrophage
9%
Natural Killer Cell Response
9%
CD47
9%
T Lymphocyte Subpopulation
9%
Immune Tolerance
9%
Programmed Death 1 Ligand 1
9%
CD20 Antibody
9%
CCR9
9%
Rituximab
9%
Interleukin 7
9%
DNA Modification
9%
T Cell Subset
9%
Neck
9%
T Cell Receptor
9%
Lymphocyte Subpopulation
9%
Antineoplastic Activity
9%
Interleukin 15
9%
Secondary Lymphoid Tissue Chemokine
9%
Carcinoma Cell
9%
Cell Transport
9%
Peptides
9%
RNA Sequence
9%